Our objective was to create a simple prognostic risk score for patients with systolic heart failure and mild symptoms. We then assessed the efficacy of eplerenone across different categories of risk.
Introduction
Estimation of risk in patients with heart failure (HF) is valuable for several reasons, including the targeting of individuals for more intensive monitoring and therapy. 1 To be clinically meaningful, stratification must incorporate the contribution of several risk factors simultaneously. This is especially relevant in HF where patients have multiple co-morbidities. In order to be used routinely, such an approach should, ideally, employ a relatively simple risk score that can be memorized by physicians or summarized briefly on a card, that does not need a computer to calculate and which requires only routinely available clinical data. Such an approach has proved successful in acute coronary syndromes with the GRACE and TIMI scores. 2, 3 Further stratification of risk in this way is most likely to be useful in patients with mild symptoms because those with moderate and severe symptoms are already recognized to be at relatively high risk. We used the The Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure trial (EMPHASIS-HF) trial to develop a risk model, converted this into a user-friendly integer score, and analysed the clinical benefit of eplerenone across the spectrum of risk categories. We also illustrate how this risk score might be used to identify patients likely to obtain the greatest absolute benefit from therapy.
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Methods
Study design and patient population
The study design and principal results of the EMPHASIS-HF trial have been published in detail. 7, 8 Eligible patients had New York Heart Association (NYHA) class II HF and an ejection fraction of 35% or less and were randomized to receive eplerenone (up to 50 mg daily) or placebo, in addition to standard therapy. The trial was approved by the ethics committee at each centre and complies with the Declaration of Helsinki. The primary outcome was time to first occurrence of the composite of death from cardiovascular (CV) causes or hospitalization for HF. The trial was terminated early, according to a prespecified efficacy stopping rule, at which point 2737 patients had been randomized and followed for a median of 2.1 years. Death from CV causes or hospitalization for HF occurred in 249 (18.3%) of patients in the eplerenone group and 356 (25.9%) of patients in the placebo group. The hazard ratio for the primary outcome comparing eplerenone to placebo was 0.63 (95% confidence interval 0.54-0.74, P , 0.001). The treatment effect was found to be consistent across 20 prespecified subgroups. Individual patient baseline data available and considered for inclusion in the prognostic model included sex, age, race, smoking status, systolic (SBP), and diastolic (DBP) blood pressure, heart rate, left ventricular ejection fraction (LVEF), QRS interval, body mass index (BMI), waist circumference, albumin, alanine aminotransferase, aspartate aminotransferase, total bilirubin, creatinine, haemoglobin, potassium, sodium, estimated glomerular filtration rate (eGFR), time since HF diagnosis, aetiology of HF, prior medication, and prior medical history (previous HF hospitalization, myocardial infarction (MI), stroke, angina, hypertension, diabetes, asthma, chronic obstructive pulmonary disease, coronary artery bypass surgery (CABG), percutaneous coronary intervention, implantable cardioverter-defibrillator (ICD), pacemaker, atrial fibrillation/flutter, left branch bundle block, and cancer).
Statistical analysis
Multivariable Cox proportional-hazards modelling was used to identify strong independent baseline prognostic variables for the primary outcome. Baseline data were very complete with ,4% of patients having any missing data. Multiple imputation by chained equations was used to impute missing baseline values 9, 10 and model coefficients combined using Rubin's rules. Age and sex were included a priori in the model. To derive the prognostic model we used both forward and backward stepwise variable selection. In order to create a parsimonious risk model including only very strong prognostic variables we used a P-value for inclusion of P , 0.0001. Continuous variables were tested for non-linear effects and interactions were investigated using likelihood ratio tests. As our objective was to create a simple integer risk score, continuous variables included in the chosen model, were categorized into either two or three groups using a combination of established clinical cutpoints, expert advice, and graphical examination of rates across quintiles.
To simplify the risk score we assigned integer points to each prognostic factor based upon the log-hazard ratio estimates. The total risk score for each patient was calculated by summing the points across all chosen prognostic variables. From the overall distribution of the risk score across the EMPHASIS-HF population we formed three categories of low-, medium-, and high-risk patients, containing approximately equal number of events. Within each risk category and by treatment group we calculated the number of events, person-years at risk, and the overall event rate. Kaplan-Meier plots were drawn showing the cumulative incidence curves by treatment group and risk category. The hazard ratio for eplerenone vs. placebo was estimated in each risk group using a Cox proportional hazard model and the treatment by risk group interaction was evaluated using a likelihood ratio test. External validation of the model was undertaken using the subset of patients from the Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) 11 study who would have been eligible for the EMPHASIS-HF trial and who had the relevant baseline data available. The predictive accuracy of the models was estimated using Harrell's C-statistic. Hazard ratios for high and medium-vs. low-risk patients were estimated for both EMPHASIS-HF and the CHARM validation patients. Analyses of all HF hospitalizations, including repeats, were carried out using negative binomial regression models, comparing incidence rates on eplerenone and placebo in each of the three risk groups. The negative binomial method allows for the different individual patient tendencies (frailties) for repeat hospitalizations, i.e. it takes into account the skewness in the distribution of number of HF hospitalizations. Statistical analyses were carried out using Stata/MP version 12 and R version 2.15.1.
Results
In addition to age and sex, eight baseline variables (SBP, eGFR, diabetes, BMI, haemoglobin, prior HF hospitalization, prior MI/CABG, and heart rate) were found to be strong independent risk factors for the primary outcome ( Table 1 ). The risk of the primary outcome was found to be increased with older age, male sex, lower SBP, lower eGFR, diabetes, prior hospitalization for HF, lower haemoglobin, prior MI/CABG, lower BMI, and higher heart rate.
A patient's risk score is calculated as follows. For each of the binary variables male sex, diabetes, prior hospitalization for HF, and prior MI/CABG one point is added. For the continuous variables age, SBP, BMI, and heart rate we found that binary categorizations adequately explained the variation in risk. One point is added to the risk score for age 75 years and above, SBP ,130 mmHg, BMI ,25 kg/m 2 , and heart rate .80 b.p.m. For eGFR and haemoglobin we found that three level categorizations were required. Two points are added for eGFR ,60 mL/min/1.73 m 2 or haemoglobin less than 11 g/dL; one point is added for eGFR 60 to 69 mL/min/ 1.73 m 2 or haemoglobin 11-12.9 g/dL.
Hence, summing across these 10 factors, we have a risk score that can take integer values ranging from 0 to 12. For example, consider a 70-year-old male, with SBP 120 mmHg, eGFR 65 mL/min/1.73 m 2 , without diabetes, with a prior hospitalization for HF, haemoglobin of 10 g/dL, no prior history of MI or CABG, BMI 30 kg/m 2 , and heart rate 85 b.p.m. For this patient no points are accrued for age, diabetes, prior MI/CABG, or BMI. One point is assigned for each of male, SBP, eGFR, prior HF hospitalization, and heart rate and two points are assigned for haemoglobin. This adds up to an overall risk score of seven points for this patient.
Across all the EMPHASIS-HF patients the score had a bell-shaped distribution, ranging from 0 to 11 points with a median value of 5 ( Figure 1) . From the overall risk score we formed three groups of low-(0-4), medium-(5-6), and high (7-12) risk. These accounted for 47.2, 33.7, and 19.2% of patients and 27, 39, and 34% of primary endpoint events, respectively. The distribution of the risk score was very similar in the eplerenone and placebo groups with 271 (19.9%) and 252 (18.4%) high-risk patients in the eplerenone and placebo groups, respectively. In placebo patients, the rates for the primary outcome were 7.6, 19.0, and 39.4 per 100 patient-years in the low-, medium-, and high-risk groups, respectively ( Table 2) . On eplerenone, these rates were reduced to 5.6, 12.2, and 24.2 per 100 patient-years, respectively. Figure 2 presents the Kaplan-Meier cumulative incidence for the primary outcome by treatment group and risk category and shows that this simple integer score markedly separates high-risk from low-risk patients, and also illustrates the impact of eplerenone in all three risk categories. The cumulative incidence at 2 years in the highrisk category is 54.1 and 39.2% in the placebo and eplerenone groups, respectively. In the medium-risk category the same comparison is 32.0 and 21.1% and in the low-risk category 13.4 and 11.4%. The hazard ratios (eplerenone vs. placebo) were similar in the low-(0.74, 95% CI 0.56 -0.99), medium-(0.64, 95% CI 0.50 -0.82), and high-risk (0.63, 95% CI 0.49-0.82) categories ( Table 2 ). There was no evidence of an interaction between treatment group and risk category (P ¼ 0.68) on the hazard ratio scale. Since the relative reduction in hazard was similar in the three risk categories the absolute rate reduction is much greater in the high-risk group ( Table 2) . The absolute rate difference per 100 patient-years was 215.2 (95% CI 223.6 to 26.9), 26.8 (95% CI 210.5 to 23.1) and 22.0 (95% CI 23.9 to 20.1) in the high-, medium-, and low-risk categories, respectively (P-value for interaction on an absolute scale, P ¼ 0.001). Table 2 and Figure 3 show similar style findings for all-cause mortality. For all-cause death, the separation by risk groups is still substantial and there is some evidence of a mortality reduction due to eplerenone in all the three groups. Coefficient is log-hazard ratio.
b P-value from a likelihood ratio test.
The overall incidence of HF hospitalization shows a similar pattern of clear risk separation and marked eplerenone benefit in all three risk groups (see Table 3 and Figure 4) .
In order to validate our integer risk score we used the CHARM trial database, specifically that subset of patients with NYHA class II and ejection fraction ≤35% who also had baseline biochemistry available, which therefore is confined to North America. Three hundred and forty-two such patients were identified in CHARM of whom 101 had a CV death or HF hospitalization during a median 3.3 years follow-up. Figure 5 compares the CHARM and EMPHASIS-HF estimated 2-year primary event rate for patients in low-, medium-, and high-risk groups. In both instances the placebo and treatment arms have been combined for this purpose. Whilst the trend in risk is not so marked for the CHARM patients, this shows good agreement, and demonstrates the ability of our simple integer score to discriminate low-, medium-and high-risk patients in other populations of HF with mild symptoms. The hazard ratios for the primary endpoint for high-and medium-vs. low-risk patients were 3.30 (95% CI 2.06, 5.30) and 1.75 (95% CI 1.07, 2.86), respectively, in the CHARM patients compared with 4.39 (95% CI 3.61, 5.33) and 2.32 (95% CI 1.92, 2.80), respectively, in EMPHASIS-HF. Harrell's C-statistic for our integer risk score applied to CHARM was 0.643 compared with 0.685 when applied to EMPHASIS-HF. Not surprisingly the predictive accuracy of our integer risk score is slightly lower among the validation patients, though the difference was not statistically significantly (P ¼ 0.16).
Harrell's C-statistic for the non-integer risk score, i.e. using the log-hazard ratios was 0.692 compared with 0.685 for the integer score in EMPHASIS-HF. The same comparison was 0.658 (non integer) vs. 0.643 (integer) for the CHARM validation patients. In both data sets there is only a slight loss of predictive accuracy through the process of assigning integer scores.
Discussion
It has been established from three major international placebocontrolled trials (RALES, EPHESUS, and EMPHASIS-HF) that mineralocorticoid antagonists improve survival and reduce morbidity in a wide spectrum of patients with left ventricular dysfunction and HF. 8, 12, 13 Since the EMPHASIS-HF trial was confined to HF patients with mild symptoms (i.e. NYHA class II at entry), one might have thought that its findings relate only to patients with a relatively good prognosis, but this is not the case. The results presented here clarify that within this EMPHASIS-HF population there is in fact a huge variation in individual patient risk. One can look at individual risk factors as subgroups (e.g. older age, impaired renal function, raised heart rate) and show their impact on outcomes, and that the risk reduction with eplerenone is consistent across all such subgroups. However, a more clinically meaningful approach to risk is to combine the contributions from several risk factors simultaneously. This is particularly important in HF where patients are elderly and have multiple co-morbidities. This is not, however, done routinely because of the absence of simple risk scores that can be used by the physician at the bedside and which require only readily available clinical measurements. The greatest potential value of these scores is in patients with mild symptoms for four related reasons. The first is that as those with more severe symptoms are already recognized to be at substantial risk and managed accordingly. The second reason is that in many health-care systems intensity of monitoring/ follow-up and treatment is targeted to those at highest risk because of economic considerations meaning that those at greatest risk among patients with mild symptoms may receive less than optimum care. Thirdly, a simple means to identify patients at higher risk is needed for clinical trials. These are becoming increasingly large and costly because of the successive reduction in mortality and morbidity with recent drug and device therapies. Lastly, and related to all of the above, although effective treatments targeted to those at highest risk is most cost-effective because the greatest absolute risk reduction is in those at the highest risk, patients at the lowest risk may still derive clinically meaningful benefit, since the relative risk reduction is consistent across risk strata. Accordingly, we have used statistical modelling techniques to derive a risk score that incorporates commonly recognized risk factors in HF. Our focus was on the primary endpoint in EMPHASIS-HF (and the most commonly used primary outcome in recent HF trials), time to first HF hospitalization or CV death. Cox proportional hazards analyses were used to identify the 10 key risk factors which quantified individual patient risk. These were: age, gender, systolic blood pressure, eGFR, diabetes, prior hospitalization, haemoglobin, prior MI/CABG, BMI and heart rate. There were no surprises in this list, but what mattered was how to combine their risk contributions quantitatively. Since any risk model needs to be easy-to-use by busy clinicians, we simplified ours into an integer score ( The consequent integer score ranges from 0 to 12, the higher the score the greater the risk of having a primary endpoint. By forming three risk groups, low-(0-4), medium-(5 -6) and high (7-12) points we illustrate a very marked gradient in risk. Going from low-to-medium risk more than doubles the primary endpoint rate, and going from medium-to-high risk the rate is more than doubled yet again. This is true for both patients on placebo and on eplerenone.
It was notable that the hazard ratio comparing eplerenone with placebo was similar in all three risk groups, with around a one-third reduction with eplerenone. As a consequence, the absolute rate difference between eplerenone and placebo varied markedly by risk group with reductions in the primary endpoint rate of 2.0, 6.8, and 15.2 events per 100 patient-years of treatment in the low-, medium-, and high-risk groups, respectively. A broadly similar pattern emerged when we looked at all-cause mortality by risk group and by treatment. Comparing low-and high-risk groups the death rate was over three times higher for the latter, whether on placebo or eplerenone. The relative treatment difference for mortality was similar in all three risk groups: around a 25% reduction in mortality hazard on eplerenone. Consequently, the absolute treatment difference in mortality was also large: in low-and high-risk patients the estimated death rate reductions due to eplerenone were 1.0 and 4.1 deaths per 100 patient-years, respectively.
It is becoming increasingly recognized that concentrating solely on the conventional 'time-to-first event' analysis of events in trials fails to capitalize on the valuable information contained in repeat hospitalizations. Hence, we have included the results for all HF hospitalizations including repeats (Table 3 and Figure 4 ), which better captures the overall burden of HF morbidity. The reductions in the incidence rates comparing eplerenone with placebo are as marked for all HF hospitalizations, as just first hospitalizations, in all three risk groups. So, again, the absolute reduction in overall disease burden is better represented by the former: that is, for low-, medium-, and high-risk patients the estimated reduction in HF hospitalizations (first or repeat) attributed to eplerenone was 1.9, 16.5, and 26.1 per 100 person-years of follow-up, respectively. These analyses illustrate the potential for this type of score to readily identify subsets of highrisk patients in which a treatment is likely to be most cost-effective.
This study has certain limitations. The categorization of continuous variables into two or three groups inevitably adds some arbitrariness and results in loss of predictive accuracy. However, we have shown that the reduction in predictive accuracy is relatively small and this loss should be considered alongside gains in ease of use. Similarly converting model coefficients into integer points inevitably results in some loss of accuracy and some risk factors may be under or over represented. For example, the age over 75 years (hazard ratio 1.24) and prior HF hospitalization (hazard ratio 1.67) both carry 1 point each. However, we have shown that the loss of predictive accuracy is relatively small (Harrell's C 0.685 vs. 0.692) and again should be balanced against the gain in simplicity. The integer score we have developed, and its ability to discriminate across risk groups, has only been validated on one small external cohort of patients from the CHARM trial. The external validation showed some reduction in predictive performance (Harrell's C 0.643 vs. 0.685) and the trend in risk across the three risk groups was less marked. However, the validation also demonstrates the usefulness of our simple score in identifying higher risk patients. The score is based on 10 established variables, each previously shown to be related to patient prognosis, and so we are confident that the consequent score is readily generalizable. However, it would be useful to validate the score's predictive discrimination in other HF populations. Patients recruited in EMPHASIS-HF were a deliberately restricted subset of patients (NYHA class II, ejection fraction ,35%), so that one needs to be cautious in extrapolating the observed benefits of eplerenone to other types of patients who did not meet these eligibility criteria.
In conclusion, we have shown that an easy-to-use integer risk score based on 10 readily available items has a powerful ability to discriminate low-and high-risk patients with systolic HF and mild symptoms. The relative benefits of eplerenone in reducing mortality and HF hospitalization appear to apply across the whole spectrum of individual patient risk.
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